ZYBT

Zhengye Biotechnology Holding Limited (ZYBT) Risks & Opportunities Analysis (2026)

Invetso Score: 6.7/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Risks

Score: 6.1 (Moderate)

Weak near-term liquidity, with a 1.14 current ratio and 0.82 quick ratio, could constrain working-capital flexibility versus better-capitalized peers if demand softens.

Negative interest coverage and modest leverage suggest limited earnings cushion, leaving ZYBT more exposed than peers with stronger operating profit generation if financing costs rise.

A 60-day cash conversion cycle, driven by 84-day receivables and 195-day inventory, increases cash drag versus faster-turn peers and can pressure growth funding.

Inventory and receivables intensity may amplify margin volatility if end-market demand slows, while peers with leaner working-capital models can absorb shocks more easily.

Net cash position helps offset balance-sheet risk, but the absence of clear free-cash-flow visibility still leaves ZYBT less resilient than peers with proven cash generation.

Opportunities

Score:

Net cash and low debt-to-equity provide balance-sheet flexibility, giving ZYBT more room than leveraged peers to support growth through cyclical demand swings.

If working-capital efficiency improves, the large inventory and receivables base could release cash faster than peers, improving liquidity and funding capacity.

Low leverage reduces refinancing pressure relative to indebted peers, which can preserve strategic optionality if industry conditions tighten or capital markets become less favorable.

A modest capital structure can support faster reinvestment than peers constrained by debt service, potentially improving positioning in periods of demand recovery.

Overall Score

Score:

ZYBT’s net-cash balance sheet and low leverage support resilience versus peers, but weak liquidity, negative interest coverage, and heavy working-capital intensity limit forward flexibility.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Zhengye Biotechnology Holding Limited. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →